Eledon Pharmaceuticals Inc (ELDN)

May 14, 2025, 4:01 PM EDT - 21 days ago

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 6, 2025, 1:15 PM EDT - 4 weeks ago

Undercovered Dozen: Gevo, Eledon, Dorian, Iridium +

GEVO IRDM LPG

May 3, 2025, 8:15 AM EDT - 4 weeks ago

Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet

Mar 20, 2025, 4:01 PM EDT - 2 months ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Mar 4, 2025, 4:05 PM EST - 3 months ago

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Feb 7, 2025, 10:00 AM EST - 4 months ago

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Jan 29, 2025, 4:05 PM EST - 4 months ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 28, 2025, 11:27 AM EST - 4 months ago

Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business

Jan 13, 2025, 7:00 AM EST - 5 months ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Nov 12, 2024, 4:01 PM EST - 7 months ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Oct 29, 2024, 3:51 PM EDT - 7 months ago

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29, 2024, 7:46 AM EDT - 7 months ago

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Oct 29, 2024, 7:45 AM EDT - 7 months ago

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Sep 11, 2024, 4:05 PM EDT - 9 months ago

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Sep 4, 2024, 7:00 AM EDT - 9 months ago

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Aug 14, 2024, 5:21 PM EDT - 10 months ago

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Jul 29, 2024, 7:00 AM EDT - 11 months ago

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Jun 3, 2024, 4:01 PM EDT - 1 year ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

May 9, 2024, 7:30 AM EDT - 1 year ago

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

May 7, 2024, 7:05 AM EDT - 1 year ago

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Mar 28, 2024, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Mar 25, 2024, 4:56 PM EDT - 1 year ago

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Mar 21, 2024, 10:31 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Feb 13, 2024, 7:01 PM EST - 1 year ago

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 4, 2024, 4:40 PM EST - 1 year ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Nov 29, 2023, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

Nov 9, 2023, 4:01 PM EST - 1 year ago

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Nov 8, 2023, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Nov 2, 2023, 9:05 AM EDT - 1 year ago

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Oct 23, 2023, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

Oct 13, 2023, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Oct 2, 2023, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

Sep 25, 2023, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

Sep 20, 2023, 4:05 PM EDT - 1 year ago

Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 11, 2023, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

Sep 5, 2023, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference

May 12, 2023, 1:03 PM EDT - 2 years ago

Eledon Pharmaceuticals, Inc. (ELDN) Q1 2023 Earnings Call Transcript

May 10, 2023, 2:45 PM EDT - 2 years ago

Eledon Pharmaceuticals: Disrupting The Kidney Transplantation Landscape

Mar 31, 2023, 6:00 AM EDT - 2 years ago

Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology

Mar 30, 2023, 8:28 PM EDT - 2 years ago

Eledon Pharmaceuticals, Inc. (ELDN) Q4 2022 Earnings Call Transcript

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results

Mar 23, 2023, 4:05 PM EDT - 2 years ago

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023

Feb 8, 2023, 4:05 PM EST - 2 years ago

Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

Jan 9, 2023, 8:31 AM EST - 2 years ago

Eledon Pharmaceuticals Provides Business and Pipeline Updates

Dec 21, 2022, 4:05 PM EST - 2 years ago

C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System

Nov 14, 2022, 8:35 PM EST - 2 years ago

Eledon Pharmaceuticals, Inc. (ELDN) Q3 2022 Earnings Call Transcript